More than 1 in 10 U.S. adults is currently taking a GLP-1 weight-loss drug. And these medicines are getting cheaper seemingly ...

Rosie O’Donnell has said her physical transformation is “completely shocking” ...

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

As 2026 brings the first wave of Medicare drug price negotiations under the Inflation Reduction Act, the landscape for high-cost cardiovascular medications like Repatha (evolocumab) has shifted ...

In the U.S., many top brand-name drugs continue to get more expensive with age, while the same medicines often get cheaper in peer countries, according to an AARP Public Policy Institute ...

Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation.

President Donald Trump’s drug-pricing platform TrumpRx is expanding to offer 600 generic medications — and partner with billionaire “Shark Tank” investor Mark Cuban. The growth of the federally run ...

Amgen AMGN stock has declined 12.6% in the past three months. Investors are increasingly worried about a mix of near-term revenue pressure, patent expirations, obesity-drug competition and uncertainty ...

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...

Amgen Inc () has held its Q1 earnings call. Read on for the main highlights of the call. Meet Samuel – Your Personal Investing Prophet. Start a conversation with TipRanks’ tru ...

One of the most common questions I hear from patients is, "My cholesterol was flagged as abnormal, but you told me everything looked good. How can that be?" Recently, a patient named Rose asked ...